Latest Findings Famotidine is Safe and Effective Against COVID-19

 

In a phase II trial, famotidine for mild-to-moderate COVID-19 was found to be safe and effective.

Latest Findings Famotidine is Safe and Effective Against COVID-19
Image: COVID-19 Virus | InStyleHealth


According to the findings of a phase II trial, using famotidine in the treatment of outpatients with mild-to-moderate COVID-19 is safe and well tolerated, resulting in quick remission of symptoms and inflammation without lowering anti-SARS-CoV-2 immunity.

 

A total of 55 adult patients (median age 35 years, 64% female, 33% African American) were randomly assigned to receive either 80 mg famotidine (n=28) or placebo (n=27) three times a day for 14 days. Self-administered treatment was used.

 

There were no significant differences in total symptom scores (median 18 for both) or average symptom durations across groups (median 4 days for both). Most patients' physiological data were within normal limits, including an average oxygen saturation of 99 percent.

 

The primary goal was the time to symptom remission; the rate of symptom resolution was secondary, and the resolution of inflammation was exploratory.

 

The trial was completed by 52 participants (95 percent), who contributed 1,358 electronic symptom surveys. There was no significant improvement in time to symptom resolution with either medication group (p=0.4), although patients taking famotidine had a greater rate of symptom resolution (p0.0001).

 

Famotidine reduced overall baseline symptom scores by 8.2 days (95 percent confidence interval [CI], 7–9.8) compared to 11.4 days (95 percent confidence interval [CI], 10.3–12.6) with placebo. There were no differences based on gender, race, or ethnicity.

 

Two patients on famotidine and three on placebo experienced self-limiting adverse effects (40 percent and 60 percent, respectively). On day 7, famotidine patients showed lower interferon alpha plasma levels (p=0.04). The two therapy groups had similar levels of plasma immunoglobulin type G to SARS-CoV-2 nucleocapsid core protein.

 

Source: Gut BMJ 2022-326952

Previous Post Next Post